We and our colleagues and at GARDP and DNDi are deeply saddened by the passing of Martin Khor, a friend and trusted advisor to colleagues and partners around the world working to advance medical innovation and access to treatment for vulnerable and neglected people.
At the Global Antibiotic Research and Development Partnership (GARDP), we’re not only developing treatments for drug-resistant infections, but lifesaving antibiotics for the world’s most vulnerable, including the very young, elderly and immunocompromised. We’re acutely aware some of these groups are being hit hardest by the Coronavirus disease (COVID-19) outbreak.
An overview of GARDP achievements during 2019, including the launch of a new strategy, a new programme and progress on the research and development of treatments for drug-resistant infections.
It is with great pleasure that I share with you our 2018 Activity Report, which reflects the progress we have made in addressing Gram-negative drug-resistant infections in children, newborns with sepsis, and sexually-transmitted infections. 2019 is an important year for taking concrete action to address antimicrobial resistance. For our part, we are launching an ambitious, new […]
Dear Friends, 2018 has been a landmark year for GARDP. We have made significant progress to address important global health priorities such as drug-resistant infections in children, newborns with sepsis, and sexually-transmitted infections. None of this would have been possible without your support. Partnerships are at the heart of our approach to develop new treatments. […]